Strategic Partnerships Target academic, government, and biotech incubators in Maryland and the broader US with interest in rapid diagnostic platforms. Leverage past TEDCO funding and SC2i collaboration to position Astek as a preferred partner for co-development, pilot programs, and grant-funded projects that accelerate regulatory approval.

Regulatory Readiness Highlight readiness for FDA submission and phased market entry with a urine-based UTI test that delivers antibiotic sensitivity in about an hour. Use this to approach hospital systems, consolidation labs, and reference labs seeking faster diagnostic turnaround and cost reduction.

Clinical Adoption Focus on high-value clinical segments such as infectious disease, urology, neurology (CSF testing), and critical care where rapid pathogen confirmation and susceptibility data can reduce patient complications and length of stay, driving demand for pilot deployments.

Funding Momentum Capitalize on recent TEDCO investments and Maryland-based innovation awards to approach regional investors and grant programs for scale-up, manufacturing partnerships, and field trials that demonstrate clinical and economic impact.

Competitive Positioning Differentiate from peers by emphasizing rapid one-hour results across multiple sample types, potential cost savings for healthcare systems, and the Jiddu platform’s versatility. Target mid-sized diagnostic labs and hospital systems seeking alternatives to slower, traditional culture methods.